Results 51 to 60 of about 6,483 (202)

Oct2 enhances antibody-secreting cell differentiation through regulation of IL-5 receptor α chain expression on activated B cells [PDF]

, 2008
Mice lacking a functional gene for the Oct2 transcriptional activator display several developmental and functional deficiencies in the B lymphocyte lineage. These include defective B cell receptor (BCR) and Toll-like receptor 4 signaling, an absence of B-
Kathy D'Costa, Jhagvaral Hasbold, Corcoran, LM, Philip O. Hodgkin, Dianne Emslie, Hodgkin, PO, Kiyoshi Takatsu, Emslie, D, Metcalf, D, Lynn M. Corcoran, Donald Metcalf, Takatsu, K, Hasbold, J, 'Costa, KD   +13 more
core   +1 more source

Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2

, 2023
Abstract A wide range of endogenous and xenobiotic organic ions require facilitated transport systems to cross the plasma membrane for their disposition 1, 2 . In mammals, organic cation transporter subtypes 1 and 2 (OCT1 and OCT2, also known as SLC22A1 and SLC22A2, respectively ...
Yang Suo, Nicholas J. Wright, Hugo Guterres, Justin G. Fedor, Kevin John Butay, Mario J. Borgnia, Wonpil Im, Seok-Yong Lee   +7 more
openaire   +2 more sources

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover [PDF]

The Journal of Pharmacology and Experimental Therapeutics, 2017
Organic cation (OC) transporter 2 (OCT2) mediates the first step in the renal secretion of many cationic drugs: basolateral uptake from blood into proximal tubule cells. The impact of this process on the pharmacokinetics of drug clearance as estimated using a physiologically-based pharmacokinetic approach relies on an accurate understanding of the ...
Alyscia Cory, Severance, Philip J, Sandoval, Stephen H, Wright   +2 more
openaire   +2 more sources

The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics

Molecules, 2022
With the widespread clinical use of drug combinations, the incidence of drug–drug interactions (DDI) has significantly increased, accompanied by a variety of adverse reactions.
Birui Shi, Yan Zhang, Baolin Huang, Huiping Lin, Qiong Zhou, Yujue Wang, Zheng Cai, Menghua Liu   +7 more
doaj   +1 more source

Effect of Late Second to Early Third Trimester of Pregnancy on the Activity of Renal Organic Anion Transporters (OAT1 and OAT3): A Biomarker Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnant individuals take drugs throughout pregnancy and many of these drugs (e.g., antivirals, antibiotics) are eliminated by renal organic anion transporters (OAT) 1 and OAT3. In vivo studies with OAT1/3 substrate drugs suggest that pregnancy increases renal OAT1/3 activities by 1.5‐ to 1.8‐fold.
Aarzoo Thakur, Jashvant D. Unadkat, Emily E. Fay, Nina Isoherranen, Mary F. Hebert   +4 more
wiley   +1 more source

Combinatorial Pharmacophore Modeling of Organic Cation Transporter 2 (OCT2) Inhibitors: Insights into Multiple Inhibitory Mechanisms

, 2016
Organic cation transporter 2 (OCT2) is responsible for the entry step of many drugs in renal elimination, of which the changing activity may cause unwanted drug–drug interactions (DDIs).
Mingyue Zheng (180908), Xian Liu (191882), Shanshan Li (114847), Hualiang Jiang (19452), Yuan Xu (161775), Likun Gong (172599), Cheng Luo (48047), Xiaomin Luo (19447), Nannan Zhou (324509), Kaixian Chen (19449)   +9 more
core   +1 more source

Interaction of gilteritinib with OCT1 and OCT2 transporters; relation to conventional therapy of acute myeloid leukemia. [PDF]

, 2021
Univerzita Karlova Farmaceutická fakulta v Hradci Králové Katedra Farmakologie a toxikologie Student: Kateřina Novotná Supervisor: doc. PharmDr. Martina Čečková, Ph.D.
Novotná, Kateřina
core  

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2.

, 2016
The requirement for the B-cell transcription factor OCT2 (octamer-binding protein 2, encoded by Pou2f2) in germinal center B cells has proved controversial.

core   +1 more source